Arcellx, Inc. Hits New 52-Week High of $114.26, Up 110% Yearly

Arcellx, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 114.26 on February 23, 2026. This achievement marks a remarkable performance over the past year, with the stock appreciating by 110.14%, significantly outpacing the S&P 500's gain of 12.95% during the same period. The company's market capitalization stands at approximately USD 3,707 million, reflecting its position within the small-cap segment. Despite the impressive stock performance, Arcellx is currently operating at a loss, as indicated by its non-applicable price-to-earnings (P/E) ratio. The company does not offer a dividend, and its debt-to-equity ratio is reported at -1.03, suggesting a unique financial structure. Additionally, the return on equity is at -49.44%, and the price-to-book ratio is 8.41. This recent high underscores the stock's volatility and the dynamic nature of the biotechnology industry, where companies often experience rapid changes in market sentiment and performance metrics.